Site Map

Alternative Medicine »

Pn 400 Phase Iii Studies Show Clinically Meaningful Benefit In Reducing Gastric Ulcers Compared To Enteric-coated Naproxen

Wed, 3 Dec 2008 Similar Items Print Press Release Submissions »

AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric… Read »

 

Similar Items:
Maximum LIFE’S Product Navitol Clinically Proven To Reduce Systolic Blood PressureMaximum LIFE’S Product Navitol Clinically Proven To Reduce Systolic Blood Pressure
Ginkgo Evaluation Of Memory (gem) Study Fails To Show Benefit In Preventing Dementia In The ElderlyGinkgo Evaluation Of Memory (gem) Study Fails To Show Benefit In Preventing Dementia In The Elderly
All-natural Treatment For Ulcers And Stomach Illness Helps Absorb Harmful BacteriaAll-natural Treatment For Ulcers And Stomach Illness Helps Absorb Harmful Bacteria
Study Finds Ionsys™, A New Needle-free System For Management Of Acute Postoperative Pain, Requires Less Staff Time And Resources Compared To Iv Pca TreatmentStudy Finds Ionsys™, A New Needle-free System For Management Of Acute Postoperative Pain, Requires Less Staff Time And Resources Compared To Iv Pca Treatment
Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/womenHormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/women
Neurotech Announces Completion Of Enrollment Of Its Phase Ii/iii Retinitis Pigmentosa And Phase Ii Dry Age Related Macular Degeneration Clinical StudiesNeurotech Announces Completion Of Enrollment Of Its Phase Ii/iii Retinitis Pigmentosa And Phase Ii Dry Age Related Macular Degeneration Clinical Studies
Eating More Fish A Wise New Year Resolution, Studies ShowEating More Fish A Wise New Year Resolution, Studies Show
Bayer Reports Progress In Clinical Program For RiociguatBayer Reports Progress In Clinical Program For Riociguat
Gamma Secretase Modulators Show Promise In ALZHEIMER’S Disease Animal Model Efficacy Studies, According To Research Conducted By Torreypines TherapeuticsGamma Secretase Modulators Show Promise In ALZHEIMER’S Disease Animal Model Efficacy Studies, According To Research Conducted By Torreypines Therapeutics
Lifesaving Benefits Of Low-dose Aspirin Therapy Maintained With Naproxen SodiumLifesaving Benefits Of Low-dose Aspirin Therapy Maintained With Naproxen Sodium